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Abstract
Introduction Glucocorticoids are a mainstay of anti-
inflammatory therapy, but significant adverse effects ultimately
limit their utility. Previous efforts to design glucocorticoid
structures with an increased therapeutic window have focused
on dissociating anti-inflammatory transcriptional repression from
adverse effects primarily driven by transcriptional activation. An
alternative to this medicinal chemistry approach is a systems
biology based strategy that seeks to amplify selectively the anti-
inflammatory activity of very low dose glucocorticoid in immune
cells without modulating alternative cellular networks that
mediate glucocorticoid toxicity.
Methods The combination of prednisolone and the
antithrombotic drug dipyridamole was profiled using in vitro and
in vivo models of anti-inflammatory activity and glucocorticoid-
induced adverse effects to demonstrate a dissociated activity
profile.
Results The combination synergistically suppresses release of
proinflammatory mediators, including tumour necrosis factor-α,
IL-6, chemokine (C-C motif) ligand 5 (RANTES), matrix
metalloproteinase-9, and others, from human peripheral blood
mononuclear cells and mouse macrophages. In rat models of
acute lipopolysaccharide-induced endotoxemia and delayed-
type hypersensitivity, and in chronic models of collagen-induced
and adjuvant-induced arthritis, the combination produced anti-
inflammatory activity that required only a subtherapeutic dose of
prednisolone. The immune-specific amplification of
prednisolone anti-inflammatory activity by dipyridamole did not
extend to glucocorticoid-mediated adverse effects, including
corticosterone suppression or increased expression of tyrosine
aminotransferase, in vivo after repeat dosing in rats. After 8
weeks of oral dosing in mice, treatment with the combination did
not alter prednisolone-induced reduction in osteocalcin and
mid-femur bone density, which are markers of steroid-induced
osteoporosis. Additionally, amplification was not observed in the
cellular network of corticotroph AtT-20/D16v-F2 cells in vitro, as
measured by pro-opiomelanocortin expression and
adrenocorticotropic hormone secretion.
Conclusions These data suggest that the multi-target
mechanism of low-dose prednisolone and dipyridamole creates
a dissociated activity profile with an increased therapeutic
window through cellular network selective amplification of
glucocorticoid-mediated anti-inflammatory signaling.
Introduction
The robust anti-inflammatory effects of glucocorticoids are
applied broadly in the clinical setting to treat diverse condi-
tions, including rheumatic diseases, allergy, skin disorders,
pulmonary conditions, cancer, transplant rejection, and even
spinal cord injury. Unfortunately, the long-term clinical utility of
glucocorticoids is limited by undesirable adverse effects,
including suppression of the hypothalamus-pituitary-adrenal
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(HPA) axis, increased serum glucose, induction of osteoporo-
sis and glaucoma, altered electrolyte balance, insomnia, and
other behavioral alterations. Chronic treatment with even rela-
tively low doses (for instance, 7.5 mg/day prednisolone) can
lead to a subset of glucocorticoid-induced adverse effects
[1,2]. Development of glucocorticoids with an improved thera-
peutic window has therefore been an area of focus for multiple
groups.
The diverse effects of glucocorticoids are mediated by the glu-
cocorticoid receptor (GR). Unliganded GR is retained in the
cytosol by heat shock proteins that are released upon binding
and activation by glucocorticoid [3]. Once activated the GR
translocates to the nucleus and can bind directly to glucocor-
ticoid response elements (GREs) as a homodimer, resulting in
both activation and repression of transcription, depending on
promoter structure and interaction with various co-activators
and co-repressors. Additionally, activated GR can affect tran-
scription through mechanisms independent of DNA binding
that modulate the activity of other transcription factors, includ-
ing nuclear factor-κB, activator protein-1, and STAT (signal
transducer and activator of transcription) [4]. Finally, activated
GR elicits a variety of transcription-independent effects
through modulation of mRNA stability via 3'-untranslated
region binding [5]. It is the integration of these diverse mech-
anisms, which affect multiple molecular targets, cells, and tis-
sues, that results in the desirable anti-inflammatory activity and
undesirable adverse effects of glucocorticoid treatment.
Efforts to dissociate the anti-inflammatory activity from the
adverse effects of glucocorticoids have focused primarily on
separating the DNA-binding-dependent (transcriptional acti-
vating) and DNA-binding-independent (transcriptional
repressing) activities of activated GR. Dimerization-defective
mutants of GR that lack DNA-binding activity can repress acti-
vator protein-1 mediated transcription, but they cannot acti-
vate transcription of GRE-regulated genes [6]. Glucocorticoid
treatment can suppress local and systemic inflammation in
homozygotic mice that express this GRdim mutation, under-
scoring the importance of DNA-binding-independent mecha-
nisms to the anti-inflammatory effect observed in vivo [7]. In
contrast, many adverse effects of glucocorticoid treatment are
due to DNA-binding-dependent activation (hyperglycemia,
hypertension) or repression (suppression of HPA axis, oste-
oporosis) of transcription through activated GR homodimer
binding to GREs [8,9]. A number of selective GR modulators
or selective GR agonists (SEGRAs) have been developed that
can dissociate anti-inflammatory activity from some of the clas-
sical glucocorticoid adverse effects [10-15].
Early attempts at steroid dissociation using medicinal chemis-
try have yielded mixed degrees of success because the anti-
inflammatory activity and adverse effects of glucocorticoids do
not break cleanly along the mechanistic lines of transcriptional
repression and transcriptional activation. For example, adverse
glucocorticoid effects including suppression of HPA axis,
osteoporosis, and skin atrophy are probably induced, at least
in part, by DNA-binding-independent repressive effects [8].
Similarly, the anti-inflammatory targets annexin-1 (lipocortin-1)
[16], glucocorticoid-induced leucine zipper [17,18], and tris-
tetraprolin [19] are positively regulated by DNA-binding-
dependent transcriptional activating effects of glucocorti-
coids. Finally, macrophages from GRdim  mice exhibit a
decreased potency of glucocorticoid suppression of IL-1β,
monocyte chemotactic protein-1 (CCL2), macrophage inflam-
matory protein-2 (CXCL2), and interferon-gamma-inducible
protein-10 (CXCL10) [20]. It is likely that effective dissociation
of glucocorticoid action to enhance therapeutic index will
require a careful tuning of both DNA-binding-dependent (tran-
scriptional activating) and DNA-binding-independent (tran-
scriptional repressing) effects to achieve an improved balance
of desirable anti-inflammatory activity over induction of
adverse effects [21]. This type of multi-parametric optimization
presents a significant challenge to the medicinal chemistry
approach to glucocorticoid dissociation.
An alternative approach to dissociation makes use of synergis-
tic multi-target biology to amplify selectively the anti-inflamma-
tory activity of glucocorticoids in immune cells without
affecting glucocorticoid-induced adverse effects in alternative
cellular networks [22,23]. The combined molecular effects of
the antithrombotic agent dipyridamole and a very low dose of
the glucocorticoid prednisolone create such an activity profile.
Dipyridamole inhibits the activity of equilibrative nucleoside
transporters and phosphodiesterases to increase cAMP and
cGMP that block platelet activation, and it is used therapeuti-
cally in combination with low-dose aspirin for secondary stroke
prevention [24]. Dipyridamole has also demonstrated anti-
inflammatory activity using cell-based in vitro models [25]. The
synergistic combination of prednisolone and dipyridamole
suppresses tumor necrosis factor (TNF)-α secretion by
lipopolysaccharide (LPS)-stimulated human peripheral blood
mononuclear cells, as well as secretion of a unique set of
cytokines, chemokines, and proteases by mouse bone-derived
macrophages [26] (Fraser CC, unpublished data). In addition
to suppressing the rheumatoid arthritis (RA)-modifying target
TNF-α, the combination inhibits additional targets, including
chemokine (C-C motif) ligand 5 (RANTES) and matrix metallo-
proteinase-9 (gelatinase-B), which are upregulated in RA syn-
ovium [27-30], and IL-6, which has been validated as a new
target for the treatment of RA [31]. In RA, low-dose pred-
nisolone treatment is generally considered to be a daily dose
of 7.5 mg [32,33]. The combination of very low dose pred-
nisolone (3 mg/day) and dipyridamole (400 mg/day) has
exhibited statistically significant effects in human clinical trials
of hand osteoarthritis [34] and RA (Kirwan JR, unpublished
data). The selectivity of this synergistic combination was dem-
onstrated by first measuring the activity of the combination in
both acute and chronic models of inflammation in rats. The
combination was then tested in various in vivo models of glu-Available online http://arthritis-research.com/content/11/1/R12
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cocorticoid-induced adverse effects, including suppression of
the HPA axis marker corticosterone, induction of the glucone-
ogenesis gene tyrosine aminotransferase (TAT), and effects
on markers of bone homeostasis. These data support a selec-
tive activity profile for this combination, in which dipyridamole
amplifies the desired anti-inflammatory activity of prednisolone
in immune cells without enhancing glucocorticoid action in
alternative cellular networks that mediate adverse effects to
generate an improved therapeutic index.
Materials and methods
Human peripheral blood mononuclear cell cytokine 
suppression assay
Compounds were obtained from Sigma-Aldrich (St. Louis,
MO, USA), and stock solutions of appropriate concentration
(in dimethyl sulfoxide) were serially diluted on master plates
using liquid-handling automation and transferred to assay
plates. Human buffy coat was obtained fresh daily from healthy
donors and diluted in media supplemented with 10% fetal
bovine serum (FBS; HyClone (Logan, UT, USA)) prior to stim-
ulation with LPS (catalog number L-4130; Sigma-Aldrich) at 2
μg/ml and addition to assay plates. Plates were incubated for
18 hours at 37°C and 5% carbon dioxide. Supernatants were
transferred to an ELISA plate coated with anti-TNF-α antibody
(catalog number 551220; BD Pharmingen (San Diego, CA,
USA)). Plates were then washed before probing with a second
antibody (catalog number 554511; BD Pharmingen) and
europium-labeled detection reagent (catalog number 1244-
360; PerkinElmer (Waltham, MA, USA)). Raw data values of
time-resolved fluorescence were converted to relative frac-
tional inhibition (I = 1 – T/U) by comparing compound or com-
bination treated values (T) with the median vehicle-alone level
(U). Synergy is determined by comparing the combination's
response to the Loewe additivity standard [35], and compari-
sons were made numerically using the combination index (CI)
[36]. For example, CI70 = (CX/IC70X) + (CY/IC70Y), where (CX/
IC70X) for a mixture is the ratio of compound X concentration
in a 70% effective mixture (CX) over its 70% inhibitory concen-
tration when applied alone (IC70X).
Rat endotoxemia model
Lewis (LEW/SsNHsd) rats (n = 8/group) were administered
the appropriate test or control agent via oral gavage. Two
hours after test or control substance administration (time =
120 minutes), animals were injected intraperitoneally with
Escherichia coli serotype 0111:B4 LPS (Sigma-Aldrich).
Control animals received a saline injection. Animals were euth-
anized by carbon dioxide asphyxiation 90 minutes after LPS
administration. Serum samples were assayed for TNF-α levels
using an ELISA (BioSource, Camarillo, CA, USA). All study
procedures were approved by the CombinatoRx, Inc. Institu-
tional Animal Care and Use Committee.
Mouse delayed-type hypersensitivity model
CD-1 mice (n = 5/group) were sensitized with 2,4-dinitrofluor-
obenzene (DNFB) solution by application to the abdomen.
Five days after application of DNFB, mice were administered
test agents by oral gavage at the indicated doses (mg/kg).
Two hours after the administration of the test agents, animals
were challenged by painting the outer and inner surface of the
left ear with DNFB. The right ear was painted with diluent (4:1
acetone/olive oil) as a control. Twenty-four hours after chal-
lenge, mice were anesthetized and the thickness of the DNFB-
treated ear and the control ear were measured using elec-
tronic precision calipers to determine the change in thickness
(mm).
Rat collagen-induced arthritis model
Lewis (LEW/SsNHsd) rats (n = 12/group) were immunized
with type-II collagen from newborn calf joints (Elastin Products
Company, Inc., Owensville, MO, USA) emulsified in incom-
plete Freund's adjuvant (product number F5506; Sigma-
Aldrich). Approximately 2 mg/kg collagen was given to all ani-
mals via intradermal injection on day 1 of the study. Two injec-
tions of 100 μl of collagen/adjuvant were made, one into the
base of the tail and the other further up the back, separated by
approximately 1.5 cm. A boost injection of the same material
was given intradermally on day 6 of the study. Vehicle and test
agents were administered via oral gavage. Dosing volume was
5 ml/kg and was adjusted weekly based on body weight meas-
urements. Treatment period was from day 10 through day 27.
Tibiotarsal joint thickness was measured using an electronic
caliper on days 3, 6, 8, 13, 15, 17, 20, 22, 24 and 27. Change
in joint thickness was calculated relative to the day 3 measure-
ment. All study procedures were approved by the MDS
Pharma Services (Bothell, WA, USA) Institutional Animal Care
and Use Committee.
Louvain rats (n = 12/group) were immunized with solubilized
type II collagen (1 mg/ml) in incomplete Freund's adjuvant
injected intradermally into 15 sites on the back. Collagen-
induced arthritis (CIA) developed over the next 10 days and
test agents were administered every day by intragastric gav-
age from days 10 to 28 at the doses indicated (mg/kg). Arthri-
tis severity was recorded daily for each hind paw using an
integer scale from 0 to 4 to quantify the level of erythema and
swelling (0 = normal; 4 = maximum). The sum of both hind
paws (maximum score of 8) represented the severity of arthri-
tis. Hind limbs were harvested at sacrifice (day 28) and scored
by radiographic joint index on a scale from 0 to 3, based on
soft tissue swelling, joint space narrowing, periosteal new
bone formation, and presence of erosions and/or ankylosis (0
= normal; 3 = maximum joint destruction). The radiographic
joint index represented the sum of both hind paws with a max-
imum score of 6. The experimental protocol conformed to the
approved protocols of the UCLA Animal Care and Use Com-
mittee.Arthritis Research & Therapy    Vol 11 No 1    Zimmermann et al.
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Rat repeat dosing model
Lewis (LEW/SsNHsd) rats (n = 5/group) were weighed and
placed into one of the six study groups. Body weights were
recorded every other day throughout the study. Animals were
dosed daily via oral gavage with test agents at volumes based
on body weight progression throughout the study. On day 10,
2 hours after oral dosing, animals were euthanized via carbon
dioxide asphyxiation. All study procedures were approved by
the CombinatoRx, Inc. Institutional Animal Care and Use Com-
mittee.
Blood was collected and separated for corticosterone deter-
mination from serum (Diagnostic Systems Laboratories, Inc.,
Webster, TX, USA). Thymus and spleens were collected and
weighed. Liver samples were removed and stored in RNAlater
(Ambion, Austin, TX, USA) at 4°C. Liver samples were homog-
enized using TissueRuptor (Qiagen) and total RNA was iso-
lated using the RNeasy-Plus Mini kit (Qiagen, Valencia, CA,
USA). Equal amounts of total RNA were used for one step RT-
PCR (QuantiTect Probe; Qiagen). Commercially available
assay reagents (Taqman Gene Expression Assays; Applied
Biosystems, Foster City, CA, USA) were used for detection of
TAT and β-actin (endogenous control) mRNA, using the
Applied Biosystems 7300 Real-Time PCR System.
Mouse osteoporosis model
Mice (C57Bl/6) were randomized (n = 10/group) to treatment
groups based on body weight before the start of dosing. Test
agents were administered via oral gavage, with the exception
of dexamethasone, which was administered via subcutaneous
injection. All agents were dosed twice daily and new formula-
tions prepared weekly for a total treatment period of 8 weeks.
Animals were given two doses of calcein 10 mg/kg intraperi-
toneally 6 and 2 days before necropsy for fluorochrome labe-
ling. Animals were anesthetized with isoflurane before
necropsy, a terminal blood sample was collected, and serum
was separated and stored frozen until analysis for bone mark-
ers. Femurs and lumbar vertebrae were also collected for dual
energy X-ray absorptiometry, peripheral quantitative computed
tomography and histomorphometry. All study procedures were
approved by the MDS Pharma Services Institutional Animal
Care and Use Committee.
Corticotroph cAMP assay
AtT-20 cells were seeded at a density of 60,000 cells per well
in a 96-well plate for determination of changes in cAMP levels
in response to various treatment conditions. Cells were
allowed to recover for 18 hours and then treated with dipyrida-
mole (10 μmol/l), rolipram (10 μmol/l), or dimethyl sulfoxide
control for 30 minutes at room temperature. Cells were then
stimulated with corticotrophin-releasing factor (37.5 nmol/l),
or control (vehicle), for 30 minutes at room temperature. cAMP
levels were quantitated using the LANCE cAMP Detection Kit
(PerkinElmer).
Pro-opiomelanocortin expression and 
adrenocorticotropic hormone secretion assays
The murine anterior pituitary corticotroph cell line AtT-20/
D16v-F2 was obtained from the American Type Culture Col-
lection (Manassas, VA, USA) and maintained in Dulbecco's
minimal essential medium (American Type Culture Collection)
with 10% FBS, at 37°C with 5% carbon dioxide. To determine
relative pro-opiomelanocortin (POMC) expression in AtT20
cells treated with prednisolone and/or dipyridamole, real-time
RT-PCR was performed on cell lysates using the FastLane
Cell RT-PCR kit (Qiagen). Commercially available assay rea-
gents (Taqman Gene Expression Assays; Applied Biosys-
tems) were used for detection of POMC β-actin (endogenous
control) mRNA. Real time RT-PCR was done using the
Applied Biosystems 7300 Real-Time PCR System. For ACTH
secretion experiments, AtT20 cells were seeded in 24-well
plates at a density of 125,000 cells/well in Dulbecco's minimal
essential medium supplemented with 10% charcoal/dextran
FBS (HyClone), and treated with prednisolone and/or dipyri-
damole. After 24 hours, the medium was refreshed with the
same compound treatment in the absence or presence of cor-
ticotropin-releasing factor (CRF; 100 nmol/l). Three hours
later (27 hours), culture medium was collected for evaluation
of ACTH by ELISA (MD Biosciences, St. Paul, MN, USA).
Results
In vitro anti-inflammatory assays
The combination of prednisolone and dipyridamole synergisti-
cally suppresses production of proinflammatory markers in
vitro. The combination was discovered based on the observa-
tion of synergistic suppression of TNF-α from phorbol myr-
istate acetate and calcium ionophore stimulated human
peripheral blood mononuclear cells (PBMCs [see Figure S1 in
Additional data file 1]). In a secondary assay the combination
was found to synergistically suppress TNF-α secretion from
LPS-stimulated PBMCs with a CI of 0.31 ± 0.02 (Figure 1a,
left panel). Combinations with CI about 1 interact additively,
such as would be expected when combining a drug with itself,
and CI values below 1 indicate a synergistic interaction
between the components [36]. Isobolographic analysis indi-
cates that the synergistic effect of the combination allows
reduction of the drug concentrations required to achieve 70%
inhibition of TNF-α secretion by ten-fold for prednisolone and
five-fold for dipyridamole (Figure 1a, right panel).
The activity of prednisolone and the combination effect is abol-
ished by treatment with the GR antagonist RU486 at a con-
centration of 50 nmol/l, but dipyridamole activity is unaffected
(Figure 1b). Antagonism by such a low dose of RU486 sug-
gests that the effect may be mediated primarily by the GRE-
dependent transcriptional-activating activity of dimerized GR.
In vivo anti-inflammatory assays
The combination of prednisolone and dipyridamole sup-
presses TNF-α in models of acute inflammation, and diseaseAvailable online http://arthritis-research.com/content/11/1/R12
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activity in CIA in rats. High-dose prednisolone (10 mg/kg)
administered orally 2 hours before LPS challenge was able to
significantly reduce serum TNF-α in an acute model of rat
endotoxemia [37]. Prednisolone at 1 mg/kg, and dipyridamole
at 150 mg/kg, yielded nonsignificant reductions in TNF-α
release compared to the LPS control. The two agents com-
bined yielded reduction in TNF-α release that was intermedi-
ate between the effects of low-dose and high-dose
prednisolone (Figure 2a). These trends were also observed in
repeats of the LPS challenge model.
High-dose prednisolone dosed orally at 30 mg/kg was able to
suppress chemical hypersensitivity induced ear swelling (Fig-
ure 2b). A tenfold lower dose of prednisolone (3 mg/kg) and
dipyridamole (150 mg/kg) as individual agents had no effect
relative to vehicle-treated controls. The combination demon-
strated efficacy equal to high-dose prednisolone, suggesting
ten-fold amplification by dipyridamole of the anti-inflammatory
activity of low-dose prednisolone in this acute model.
Figure 1
Synergistic anti-inflammatory activity of prednisolone and dipyridamole in vitro Synergistic anti-inflammatory activity of prednisolone and dipyridamole in vitro. (a) Dipyridamole and prednisolone were diluted orthogonally using a 
twofold serial dilution, and then combined to produce a drug combination dose-response matrix. The dose responses for prednisolone and dipyrida-
mole as individual agents are located in the bottom row and left column, respectively. Combination doses fill out the matrix and component concen-
trations can be read from the row and column labels. The combination dose-response matrix was applied to lipopolysaccharide (LPS)-stimulated 
human peripheral blood mononuclear cells (PBMCs), and tumor necrosis factor (TNF)-α in the supernatant was measured by ELISA after 18 hours. 
Percentage inhibition of TNF-α secretion relative to vehicle-treated controls is indicated in each cell of the matrix and represented by a color scale, 
where warm colors indicate more inhibition (left). Isobolographic analysis of the inhibition matrix (blue line) compares the activity of the combination 
with a theoretical additive interaction (red line) at the 70% inhibition level (right). Synergistic interactions fall below the additivity threshold and 
approach the origin, and an antagonistic interaction would lie above the red additivity line. (b) Combination matrices were measured including a fixed 
dose of RU486 at the indicated concentration at each point in the corresponding dose response matrix. Percentage inhibition of LPS-induced TNF-
α secretion relative to vehicle-treated controls is indicated in each cell of the matrix.Arthritis Research & Therapy    Vol 11 No 1    Zimmermann et al.
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Disease activity was also suppressed by the combination of
prednisolone and dipyridamole in CIA models in Lewis and
Louvain rats. To test the activity of the combination in this
model of chronic inflammation, rats were sensitized with colla-
gen and hind paw arthritis developed over the next 10 days
[38,39]. Lewis rats treated with prednisolone (3 mg/kg orally)
exhibited negligible tibiotarsal joint swelling compared with
animals that were not subjected to collagen induction, and rats
treated with 0.3 mg/kg prednisolone or 150 mg/kg dipyrida-
mole showed similar levels of tibiotarsal inflammation to CIA-
induced, vehicle-treated controls (Figure 3a,b). Tibiotarsal
joint swelling trends were maintained throughout the study.
The combination of prednisolone and dipyridamole (0.3/150
mg/kg) yielded a significant reduction in swelling compared
with dipyridamole alone, and tibiotarsal swelling in the combi-
nation group was intermediate between the low-dose and
high-dose prednisolone groups at all points in the study.
The CIA model was also repeated in Louvain rats [39], and
arthritis score was measured daily from days 10 to 28 (Figure
3c,d). At the conclusion of the study (day 28) animals treated
with vehicle or dipyridamole had arthritis scores of about 6.5,
which were significantly different from the scores in the com-
bination and high-dose prednisolone groups. Combination
treated animals (0.3/150 mg/kg) had an average arthritis
score of 2.8, which was intermediate between the effect of
low-dose prednisolone (4.9) and high-dose prednisolone
(0.7), suggesting that dipyridamole can amplify the activity of
low-dose prednisolone in suppressing erythema and joint
swelling. Radiographic analysis of the hind limbs at the conclu-
sion of the study indicated that the combination significantly
reduced tissue damage relative to the vehicle control, and was
similar to low-dose steroid alone on measures of joint space
narrowing and the presence of erosions and/or ankylosis (Fig-
ure 3d).
An additional test of the combination was conducted in an
adjuvant-induced arthritis model [40], and similar anti-inflam-
matory activity of the combination was observed. A higher
dose of dipyridamole (300 mg/kg) was required to observe the
effect in this particular model. Tissue was collected and pre-
pared for histologic evaluation of tarsal and phalangeal joints
based on inflammatory infiltrate, pannus formation, and carti-
lage and bone degeneration. The combination of prednisolone
and dipyridamole achieved reduction in cartilage damage in
the tibiotarsal joint similar to that observed for the high-dose
prednisolone (5 mg/kg) positive control group. The combina-
tion strongly suppressed cartilage damage in the phalangeal
joints as well as inflammation, pannus formation, and bone
damage, as indicated by histologic analysis [see Figure S2 in
Additional data file 1].
In vivo safety assays
The observed amplification by dipyridamole of prednisolone
anti-inflammatory activity did not extend to classical glucocor-
ticoid adverse effects. Lewis rats were treated once daily for
10 days with oral dose groups of prednisolone identical to
those used in the CIA model. The amplifying dose of dipyrida-
mole was increased two-fold to 300 mg/kg for the safety stud-
Figure 2
Prednisolone and dipyridamole combine to suppress acute inflamma- tion in vivo Prednisolone and dipyridamole combine to suppress acute inflamma-
tion in vivo. (a) Lewis rats were treated orally with compounds as indi-
cated (mg/kg) for 2 hours before challenge with lipopolysaccharide 
(LPS). Serum was collected 90 minutes later and tumor necrosis factor 
(TNF)-α quantitated by ELISA. *P < 0.01 versus the LPS control; aP = 
0.06, bP = 0.98, cP = 0.81, dP = 0.59 versus the combination. (b) Mice 
were sensitized with the chemical irritant 2,4-dinitrofluorobenzene 
(DNFB). Five days later animals were administered test agents by oral 
gavage at the indicated doses (mg/kg) and challenged on the ear with 
DNFB solution. Change in ear thickness was measured 24 hours after 
challenge (Δ ear thickness [mm]). *P < 0.05 versus the vehicle control; 
aP = 0.02, bP = 1.0, cP = 0.02, dP = 0.05 versus the combination. 
Dipyridamole was dosed at 150 mg/kg. Error bars are + standard error 
of the mean. Statistical comparison is by analysis of variance with 
Tukey. Dp, dipyridamole; Pd, prednisolone.Available online http://arthritis-research.com/content/11/1/R12
Page 7 of 14
(page number not for citation purposes)
ies. This increased dose of dipyridamole had demonstrated
increased anti-inflammatory effect in some models. At the con-
clusion of dosing, appropriate tissues were harvested to
measure safety parameters. Liver mRNA levels of TAT, a
marker of glucocorticoid-activated glucose metabolism, were
evaluated by RT-PCR after repeated treatment with pred-
nisolone and dipyridamole alone, and in combination. Animals
treated daily with 3 or 5 mg/kg of prednisolone for 10 days
experienced a 2.6-fold increase in the expression of TAT
mRNA in the liver (Figure 4a). In contrast, animals treated with
0.3 mg/kg prednisolone exhibited a 1.7-fold increase in TAT
mRNA with oral daily dosing. Treatment with the combination
of prednisolone and dipyridamole (0.3/300 mg/kg) resulted in
significantly lower TAT mRNA levels than in the high-dose
prednisolone (3 mg/kg) treatment group, but was no different
from the effect of the component prednisolone dose (0.3 mg/
kg) alone (Figure 4a).
Figure 3
Prednisolone and dipyridamole combine to suppress collagen-induced arthritis in vivo Prednisolone and dipyridamole combine to suppress collagen-induced arthritis in vivo. Collagen-induced arthritis (CIA) was developed in Lewis rats 
for 10 days before oral daily dosing with compounds as indicated (mg/kg) for the next 17 days. Change in hind limb tibiotarsal joint diameter relative 
to the day 3 measurement is reported (a) over the course of the study and (b) at study completion. *P < 0.001 versus the CIA control; aP = 0.29, bP 
= 0.10, cP = 0.14, dP = 0.004 versus the combination. (c) CIA was induced in Louvain rats for 10 days and test agents were administered orally 
once daily from days 10 to 28, as indicated (mg/kg). Arthritis severity was scored daily based on erythema and swelling. *P < 0.001 versus the CIA 
control; aP = 0.0003, bP = 0.001, cP = 0.15, dP = 0.12 versus the combination at day 28. (d) Hind limbs were scored by radiographic joint index 
after the completion of the study. **P < 0.0001, *P < 0.01 versus the CIA control; aP = 0.005, bP = 0.17, cP = 0.84, dP = 0.01 versus the combina-
tion at day 28. Dipyridamole was dosed at 150 mg/kg. Error bars are ± standard error of the mean, and statistical comparison is by analysis of vari-
ance with Tukey. Dp, dipyridamole; Pd, prednisolone.Arthritis Research & Therapy    Vol 11 No 1    Zimmermann et al.
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Glucocorticoids can suppress products of the HPA axis
including, serum corticosterone. After chronic treatment of
Lewis rats with the combination or individual components for
10 days, serum was collected to quantitate levels of corticos-
terone. The 3 and 5 mg/kg prednisolone groups exhibited sig-
nificantly suppressed serum corticosterone (Figure 4b).
Prednisolone at 0.3 mg/kg had less of an effect on corticoster-
one, and this effect was not amplified when applied in combi-
nation with dipyridamole (300 mg/kg). Thymus and adrenal
gland weights were also measured following chronic dosing.
Prednisolone at 3 and 5 mg/kg suppressed thymus weight,
but 0.3 mg/kg prednisolone alone or in combination had no
significant effect on thymus weight compared with vehicle
control (Figure 4c). The effect of the combination (0.3/300
mg/kg) on adrenal weight was identical to the effect of 0.3 mg/
kg prednisolone alone, and neither was significantly different
from the vehicle control group (Figure 4d).
Chronic treatment with glucocorticoids can alter expression of
various markers of osteoporosis, including osteocalcin and
structural measures of bone density and quality. Female mice
were treated orally twice daily with various doses of pred-
Figure 4
Dipyridamole does not alter the low-dose prednisolone safety profile Dipyridamole does not alter the low-dose prednisolone safety profile. (a) Tyrosine aminotransferase (TAT) mRNA levels from liver were evaluated by 
RT-PCR after 10 days of repeat dosing in Lewis rats as indicated. β-Actin was used as the endogenous control, and results are shown as fold 
increase in TAT mRNA over vehicle. *P < 0.01 versus the vehicle control, aP = 1.0, bP = 0.01, cP = 0.90, dP = 0.30 versus the combination. (b) Cor-
ticosterone levels in serum were evaluated by ELISA after 10 days of chronic dosing. **P < 0.0001, *P < 0.05 versus the vehicle control; aP = 0.03, 
bP = 0.01, cP = 0.44, dP = 0.98 versus the combination. (c) Thymus weight was measured at the conclusion of the study. **P < 0.0001, *P < 0.01 
versus the vehicle control; aP = 0.83, bP = 0.14, cP = 0.06, dP = 0.03 versus the combination. (d) Adrenal weights were also evaluated upon study 
completion. *P < 0.05 versus the vehicle control; aP = 0.21, bP = 0.98, cP = 1.0, dP = 0.50 versus the combination. Dipyridamole was dosed at 300 
mg/kg. Error bars are + standard error of the mean, and statistical comparison is by analysis of variance with Tukey. Dp, dipyridamole; Pd, pred-
nisolone.Available online http://arthritis-research.com/content/11/1/R12
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nisolone alone, dipyridamole, or the combination of varying
doses of prednisolone with dipyridamole, for 8 weeks before
quantitation of these surrogate markers of osteoporosis. Dex-
amethasone (5 mg/kg once daily) significantly reduced osteo-
calcin and mid-shaft femur bone density compared with
vehicle-treated controls. Prednisolone was associated with a
dose-dependent reduction in osteocalcin and mid-femur bone
density that was not altered by the addition of dipyridamole
(37.5 mg/kg twice daily; Figure 5).
In vitro corticotroph assays
The observed amplification by dipyridamole of the anti-inflam-
matory activity of prednisolone did not extend to suppression
in vitro of the POMC gene and suppression of secreted ACTH
from corticotroph cells. The effects of prednisolone, dipyrida-
mole, and the combination were measured in the murine ante-
rior pituitary cell line AtT-20/D16v-F2 (AtT-20), a well studied
corticotroph model system [41]. The relative amount of cAMP
was increased in the AtT-20 cells by 1.5-fold after treatment
with dipyridamole and CRF stimulation (Figure 6a). The proto-
typic phosphodiesterase (PDE) 4 inhibitor rolipram increased
cAMP by three-fold under these conditions. CRF stimulation
increased ACTH secretion in untreated control cells after 3
hours, and pretreatment with dipyridamole (10 μmol/l) signifi-
cantly increased ACTH release compared with CRF stimula-
tion alone (Figure 6b). AtT-20 cells were pretreated with
prednisolone, dipyridamole, or the combination for 24 hours,
and then stimulated with CRF (100 nmol/l) to induce ACTH
secretion. Pretreatment with prednisolone reduced ACTH
secretion compared with the CRF-stimulated control, and the
stimulatory effects of dipyridamole (10 μmol/l) on ACTH
secretion were not observed in combination with any dose of
prednisolone (Figure 6c). Prednisolone decreased POMC
mRNA expression, with a maximum decrease of about 50%
observed at the 24-hour time point (Figure 6d). The addition of
dipyridamole (10 μmol/l) did not amplify the effect of pred-
nisolone on POMC mRNA levels, and was able to compensate
for the suppressive effect of very-low-dose prednisolone.
Discussion
The potent anti-inflammatory activity and disease-modifying
effects of glucocorticoids are well documented [42], but
safety concerns observed with chronic dosing [2] have cre-
ated a desire for safer glucocorticoids with an expanded ther-
apeutic window. Many groups are pursuing this goal with a
medicinal chemistry approach. Significant progress has been
made by identifying novel GR ligands that retain substantial
anti-inflammatory activity while reducing key glucocorticoid-
induced adverse effects [10-15]. The success of the dissoci-
ated ligands developed to date is impressive, given the
extreme complexity of the GR system and the challenge of
developing low-molecular-weight compounds that retain
desirable activities of the native ligand while selectively elimi-
nating undesirable effects. Unfortunately, these ligands gener-
ally retain unacceptable activity on one or more adverse effect
measures, suggesting that an alternative approach to gluco-
corticoid dissociation may be required.
A multi-component therapeutic can be envisaged that lever-
ages systems biology to amplify glucocorticoid activity selec-
tively in the network context of inflammatory cells over
alternative cellular networks that mediate adverse effects. In
this multi-target approach, an enhancing agent is used to sen-
sitize the immune cell network to the effects of very-low-dose
Figure 5
Dipyridamole does not amplify prednisolone effects on surrogate mark- ers of osteoporosis Dipyridamole does not amplify prednisolone effects on surrogate mark-
ers of osteoporosis. BL/6 mice were dosed twice daily with test agents 
for a total of 8 weeks to measure effects on markers of bone homeosta-
sis. (a) Serum was collected at the end of the study and osteocalcin 
was measured by ELISA. (b) End of study mid-shaft femur bone density 
was measured by flurochrome labeling, sectioning, and peripheral 
quantitative computed tomography. Prednisolone alone (grey curve); 
prednisolone in combination with dipyridamole twice daily (black 
curve); dipyridamole alone and vehicle control are indicated with open 
triangle and open circle, respectively; sub-cutaneous dexamethasone 
(5 mg/kg once daily) positive control is indicated with a black square. 
*P < 0.05 versus the vehicle control. Dipyridamole was dosed at 37.5 
mg/kg twice daily in this study (allometrically scaled from a rat total 
daily dose of 150 mg/kg). Error bars are ± standard deviation, and sta-
tistical comparison is by analysis of variance with Tukey.Arthritis Research & Therapy    Vol 11 No 1    Zimmermann et al.
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prednisolone by modulation of intersecting signaling pathways
that selectively amplify the anti-inflammatory activity of the glu-
cocorticoid. The divergent molecular context of cellular net-
works that mediate glucocorticoid adverse effects (for
example, corticotrophs or hepatocytes) do not support ampli-
fication, and therefore the safety profile of the very-low-dose
glucocorticoid is maintained. At the organism level, the effects
of the combination produce the desired anti-inflammatory
activity of a glucocorticoid with an enhanced therapeutic win-
dow.
The combination of prednisolone and the antithrombotic agent
dipyridamole synergistically suppresses the secretion of TNF-
α and other proinflammatory mediators from human PBMCs
stimulated with LPS (Figure 1a), but also phorbol myristate
acetate/Ionomycin-stimulated and α CD3/α CD28-stimulated
cultures [see Figure S1 in Additional data file 1]. Because of
the multi-target action of the components, the anti-inflamma-
tory activity is achieved at doses where prednisolone and dipy-
ridamole have marginal activity as individual agents. The
components of the combination, including dipyridamole, are
known to suppress TNF-α individually [43], but the synergistic
combination effect was unexpected [26]. In secondary assays
Figure 6
Dipyridamole does not amplify suppression of markers of the HPA axis in vitro Dipyridamole does not amplify suppression of markers of the HPA axis in vitro. (a) AtT-20 corticotroph cells were pretreated with dipyridamole (Dp; 
10 μmol/l) or rolipram (Rol; 10 μmol/l) as indicated. Cells were stimulated with corticotropin-releasing factor (CRF) or vehicle control before quanti-
tating cAMP levels. Error bars are + standard deviation (SD). *P < 0.01 versus CRF alone. (b) AtT-20 cells were pretreated with Dp or control for 24 
hours. Medium was refreshed with compounds, and then stimulated with CRF or vehicle control for an additional 3 hours. Medium was collected for 
determination of ACTH levels by ELISA. Error bars are + SD. *P < 0.001 versus CRF + Dp. (c) AtT-20 cells were pretreated with increasing doses 
of prednisolone in the absence (grey curve) or presence (black curve) of Dp (10 μmol/l) for 24 hours. Medium was refreshed with compounds plus 
CRF. After 3 hours, ACTH levels were determined by ELISA. *P < 0.001 versus vehicle alone. (d) AtT-20 cells were incubated with increasing 
doses of prednisolone in the absence (grey curve) or presence (black curve) of Dp for 24 hours. POMC mRNA levels were determined by RT-PCR 
analysis, using β-actin as the endogenous control. Dp alone (10 μmol/l) and vehicle control responses are indicated with an open triangle and circle, 
respectively. Error bars are ± SD, and statistical analysis is by analysis of variance with Tukey. HPA, hypothalamus-pituitary-adrenal.Available online http://arthritis-research.com/content/11/1/R12
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the combination was found to inhibit production of a unique
profile of cytokines, chemokines, and proteases from LPS-
stimulated mouse bone-derived macrophages, including syn-
ergistic suppression of TNF-α, IL-6, and chemokine (C-C
motif) ligand 5, which are validated targets in rheumatic dis-
ease (Fraser CC, unpublished data).
The activity of prednisolone and the synergy with dipyridamole
was blocked in vitro by the GR antagonist RU486 (Figure 1b),
demonstrating that the anti-inflammatory effect of the combi-
nation is, at least in part, GR dependent and may require
dimerization and transcriptional activation. GRE-independent
repression of nuclear factor-κB mediated transcription by glu-
cocorticoid is not significantly antagonized by 10–100 nmol/l
RU486, but GRE-dependent transcription is strongly inhibited
[44]. This result potentially differentiates the activity of the
combination from the dissociated GR ligands that are more
effective at transrepression than transactivation [12,13,15].
The combination of prednisolone and dipyridamole, but not the
components alone, has been shown to upregulate expression
of glucocorticoid-induced leucine zipper and dual-specificity
phosphatase-1 (DUSP1/MKP1) mRNA in LPS-stimulated
mouse macrophages (Fraser CC, unpublished data). DUSP1
induction has been shown in some systems to require GR
dimerization [45], but this was not observed in GRdim mouse
macrophages [46]. Together, these data suggest that tran-
scriptional activation may make an important contribution to
the anti-inflammatory activity of the combination.
The combination of prednisolone and dipyridamole was found
to have anti-inflammatory activity in both acute and chronic
models of inflammation in vivo. Low-dose prednisolone and
dipyridamole had minimal effect as single agents, but the com-
bination was able to suppress serum TNF-α in an LPS-chal-
lenge model, and ear swelling in the delayed-type
hypersensitivity model (Figure 2). These data suggest that the
molecular effect of dipyridamole may amplify the anti-inflamma-
tory activity of low-dose prednisolone between three- and ten-
fold in vivo. The ability of low-dose prednisolone to suppress
disease activity in chronic models of arthritis was also ampli-
fied by dipyridamole. The arthritis score reduction for the com-
bination was 2.1 units (4.9 for low-dose prednisolone and 2.8
for the combination), or one half the reduction observed
between low-dose (0.3 mg/kg) and high-dose (3 mg/kg) pred-
nisolone (4.9 – 0.7 = 4.2). These results suggest that amplifi-
cation may be in the range of five-fold for the arthritis models,
assuming a linear dose response (Figure 3). Prednisolone and
dipyridamole also combine to suppress histologic markers of
inflammation in an adjuvant-induced model of arthritis. Interest-
ingly, the effect of combination was most pronounced in the
phalangeal joints, where clinically relevant suppression of his-
tologic markers of inflammation, and bone and cartilage
degeneration were observed (see Figure S2 in Additional data
file 1). However, this model required a higher dose of dipyrida-
mole (300 mg/kg) that also demonstrated significant activity.
The tissue-sparing effect of the combination may stem from
the potent suppression of proinflammatory mediators from
macrophages (Fraser CC, unpublished data). The activity of
the combination observed in these animal models suggests
that the molecular effects of dipyridamole can amplify the sub-
therapeutic anti-inflammatory activity of very-low-dose pred-
nisolone to produce a disease-modifying effect.
Dipyridamole was not found to amplify the effect of pred-
nisolone on markers of glucocorticoid-induced toxicity under
the stringent conditions of repeat daily dosing in vivo.
Increased gluconeogenesis leading to hyperglycemia is a
common side effect of chronic glucocorticoid treatment [2].
The gluconeogenic potential of prednisolone and dipyrida-
mole was evaluated by measuring the effect on the classical
transcriptional activation target TAT by RT-PCR analysis of
liver tissue from rats treated with the combination or its com-
ponents. The effect of low-dose prednisolone was not altered
by simultaneous dosing with 300 mg/kg dipyridamole (Figure
4a), suggesting no enhancement of the effect of prednisolone
in hepatocytes. This result suggests that positive GRE-medi-
ated glucocorticoid adverse effects, including hyperglycemia,
may not be amplified by simultaneous dipyridamole treatment.
Adrenal insufficiency is another common adverse effect of
chronic glucocorticoid treatment [8], caused by the complex
negative feedback control of the system. Prednisolone dose-
dependently reduced serum corticosterone, and dipyridamole
did not further suppress the effect of low-dose prednisolone
(Figure 4b). This result suggests that the anti-inflammatory
synergy observed between prednisolone and dipyridamole
does not extend to the undesirable suppression of the HPA
axis. Thymus and adrenal weights were also monitored in this
study, and high-dose steroid was found to reduce these organ
weights after once-daily dosing for 10 days. No significant
effects relative to the vehicle control were observed for the
component doses alone or the combination.
Dipyridamole did not amplify prednisolone-induced effects on
markers of bone degradation in vivo. Osteoporosis is a com-
mon adverse effect of chronic treatment with glucocorticoids,
and loss of bone from spine and hip is estimated at 1.5% per
year with a daily dose of 9 mg prednisolone or equivalent [2].
Dipyridamole demonstrated no effect as a single agent and did
not alter the prednisolone dose response for osteocalcin or
mid-shaft femur bone density, suggesting a lack of combina-
tion effect on these markers (Figure 5) in mice treated for 8
weeks. The dipyridamole dose of 37.5 mg/kg twice daily in this
study was allometrically scaled from the total daily dose of 150
mg/kg used in the rat CIA studies, in which dipyridamole was
found to amplify the anti-inflammatory activity of low-dose
prednisolone. Osteocalcin is a marker of bone formation that
is known to be suppressed by glucocorticoids, caused by a
negative GRE in the promoter [47]. These data suggest that
dipyridamole does not amplify DNA-binding-dependent (GRE-
mediated) transrepressive effects of low-dose glucocorticoidArthritis Research & Therapy    Vol 11 No 1    Zimmermann et al.
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treatment. The results from this mouse study indicate that the
immune-selective action of dipyridamole may not amplify the
osteoporotic effect and fracture risk associated with very-low-
dose prednisolone [48] in the clinical setting with chronic dos-
ing.
To further explore the HPA axis effect of the combination, the
individual effects of dipyridamole were characterized in the
unique signaling network of AtT20 corticotroph cells. Dipyri-
damole treatment has been shown to inhibit PDE activity
(PDE-2, -4, -10, and -11) and increase cAMP levels [49,50].
Dipyridamole treatment of AtT-20 cells results in a modest 1.5-
fold increase in cAMP relative to CRF stimulation alone, but
was less effective than the threefold increase observed with
the potent PDE-4 inhibitor rolipram (Figure 6a). Increased
cAMP was previously shown to increase ACTH secretion in
AtT20 cells [51], and dipyridamole treatment was found to
induce a small but significant increase in CRF-dependent
ACTH secretion (Figure 6b), which may be due to increased
cAMP. Interestingly, dipyridamole does not increase cAMP in
mouse bone-derived macrophages (Fraser CC, unpublished
data), suggesting a differential effect of dipyridamole in the
immune cell network context as compared with the cortico-
troph network of the AtT20 cells. Activated GR is also known
to activate a negative GRE and to antagonize the effect of
cAMP-induced transcription factors to suppress POMC
expression [52]. We observed a prednisolone dose-depend-
ent decrease in both POMC expression and ACTH secretion
from the AtT20 cells in vitro, and this response was unaffected
by the addition of dipyridamole (Figure 6c,d). These experi-
ments demonstrate a lack of synergy between prednisolone
and dipyridamole on POMC expression or ACTH secretion in
corticotroph cells, unlike the synergistic anti-inflammatory
activity of the combination observed in human PBMCs, mouse
macrophages, and in rat arthritis models. The differential
response to combination treatment is probably due to differ-
ences in cellular network context, including expression levels
and/or spatial relationships of molecular targets, activation
state of relevant signaling pathways, and cell type-specific dif-
ferences in transcription factor expression or activation. Defin-
ing the set of targets responsible for mediating the selectivity
of the combination for immune cell networks over alternative
cell contexts is the focus of ongoing research.
The success of the SEGRAs and selective GR modulators
developed to date is impressive, given the extreme complexity
of the GR system. SEGRAs have been identified that potently
suppress irritant dermatitis [10,11,13], carrageenan-induced
and adjuvant-induced arthritis [12], and CIA [15], with
improved tolerability relative to body weight loss and elevation
of blood glucose. For example, the dissociated ligand ZK
216348 exhibited no increase in serum glucose in fasted rats
6 hours after dosing at doses up to 30 mg/kg, as compared
with an approximately 60% increase for prednisolone at 10
mg/kg [13]. TAT activity in these rats was minimally increased
by acute dosing of ZK 216348, compared with a six-fold
increase by prednisolone at an equivalent dose of 10 mg/kg
[13]. Similarly, the dissociated GR ligand LGD5552 was dem-
onstrated to be about ten-fold less potent than prednisolone in
suppressing bone formation rate in a 4-week study [15].
Unfortunately, the complexity of the GR signaling network that
controls transcriptional repression and activation, and the
post-transcriptional effects of activated GR make it extremely
challenging to develop low-molecular-weight compounds that
retain the desirable activities of the native ligand while selec-
tively eliminating undesirable effects.
Dissociation of anti-inflammatory effects and adrenal insuffi-
ciency has been especially problematic for the dissociated GR
ligand approach. Glucocorticoid release from the adrenal is
regulated by both DNA-binding-dependent and -independent
(transrepressive) effects of the GR [53]. It may be that all dis-
sociated GR ligands with transrepressive effects equivalent to
glucocorticoids will display some degree of undesirable effect
on the HPA axis. For example, acute subcutaneous treatment
of rats with ZK 216348 resulted in ACTH suppression with
potency equivalent to that of prednisolone [13]. Indeed, gluco-
corticoid activity and safety studies in GRdim mice suggest that
not all anti-inflammatory actions of activated GR are retained
in the absence of dimerization, and neither are all glucocorti-
coid-induced adverse effects eliminated [54]. Dipyridamole
was not found to amplify corticosterone suppression by low-
dose prednisolone in the rat repeat dosing study (Figure 4b),
and did not alter the prednisolone dose response for suppres-
sion of POMC and ACTH in the corticotroph cell line (Figure
6c,d). These results suggest that cellular network selective
amplification of glucocorticoid activity by the multi-target
mechanism of low-dose prednisolone and dipyridamole may
provide a solution to the challenging problem of dissociating
glucocorticoid-induced HPA axis suppression.
Conclusion
There is an increased awareness in the drug discovery indus-
try of the need for novel therapeutics that address the systems
biology of disease, and a nascent trend exists that is moving
away from the one-drug, one-target paradigm toward a more
pathway-focused or multi-target approach to drug discovery
[22,55-57]. Glucocorticoid dissociation efforts to date have
focused on modulating GR dimerization or interaction with co-
activators and co-repressors to separate the desirable and
undesirable effects of glucocorticoids. The systems biology
approach presented here exploits multi-target action to amplify
glucocorticoid activity selectively in the unique network con-
text of inflammatory cells, rather than attempting to dissect var-
ious aspects of GR biology. This approach is advantageous
because the anti-inflammatory activity of the combination is
therefore derived from amplification of native glucocorticoid
action, be it transrepressive or transactivating. Cellular net-
works that mediate traditional glucocorticoid adverse effects
do not support amplification of the low-dose glucocorticoidAvailable online http://arthritis-research.com/content/11/1/R12
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effect due to the absence of nodes or differential signaling
pathway interactions, resulting in the selective action and an
increased therapeutic window. The multi-target action of com-
bination drugs may provide a general approach to achieve cell-
type specific therapeutic effects.
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